EcoDrugPlus

F2r Like Thrombin Or Trypsin Receptor 3

Ensembl ID : ENSBBBG00000002379
Gene Symbol: F2RL3
3 Cross references
193 Possible Orthologues:

Fau Ubiquitin Like And Ribosomal Protein S30 Fusion

Ensembl ID : ENSBBBG00000005004
Gene Symbol: FAU
3 Cross references
269 Possible Orthologues:

Fkbp Prolyl Isomerase 1a

Ensembl ID : ENSBBBG00000025481
Gene Symbol: FKBP1A
2 Cross references
168 Possible Orthologues:

Fxyd Domain Containing Ion Transport Regulator 2

Ensembl ID : ENSBBBG00000023120
Gene Symbol: FXYD2
3 Cross references
71 Possible Orthologues:

Fyn Proto-Oncogene, Src Family Tyrosine Kinase

Ensembl ID : ENSBBBG00000002130
Gene Symbol: FYN
3 Cross references
264 Possible Orthologues:

G Protein-Coupled Receptor 84

Ensembl ID : ENSBBBG00000018621
Gene Symbol: GPR84
3 Cross references
124 Possible Orthologues:

Hck Proto-Oncogene, Src Family Tyrosine Kinase

Ensembl ID : ENSBBBG00000010020
Gene Symbol: HCK
3 Cross references
206 Possible Orthologues:

Il2 Inducible T Cell Kinase

Ensembl ID : ENSBBBG00000023355
Gene Symbol: ITK
3 Cross references
206 Possible Orthologues:

Janus Kinase 1

Ensembl ID : ENSBBBG00000008822
Gene Symbol: JAK1
3 Cross references
238 Possible Orthologues:

Janus Kinase 2

Ensembl ID : ENSBBBG00000015845
Gene Symbol: JAK2
3 Cross references
265 Possible Orthologues:

Janus Kinase 3

Ensembl ID : ENSBBBG00000007067
Gene Symbol: JAK3
3 Cross references
103 Possible Orthologues:

Kit Proto-Oncogene, Receptor Tyrosine Kinase

Ensembl ID : ENSBBBG00000009185
Gene Symbol: KIT
3 Cross references
211 Possible Orthologues:

Select Keywords:


PREMIER has received funding from the Innovative Medicines Initiative 2 Joint Undertaking (JU) under grant agreement No 875508. The JU receives support from the EU’s Horizon 2020 research and innovation programme and the European Federation of Pharmaceutical Industries and Associations (EFPIA). The views reflect only the authors’ perspective and the JU is not responsible for any use that may be made of the information this manuscript contains. Elements of the website have been developed under projects from the Biocenter Finland Drug Discovery and Chemical Biology network. CSC-IT is thanked for providing computational resources. Content of the website is provided without guarantee for correctness. Data has been collected and integrated from multiple public sources, for the largest: FDA, HUGO Gene Nomenclature Committee, ChEMBL, IUPHAR/BPS guide to pharmacology, Reactome, UniProt, and Ensembl. Credit is given to Ensembl for collecting species images (provided under public domain licences such as Wikimedia and NHGRI).

PREMIER has received funding from the Innovative Medicines Initiative 2 Joint Undertaking (JU) under grant agreement No 875508. The JU receives support from the EU’s Horizon 2020 research and innovation programme and the European Federation of Pharmaceutical Industries and Associations (EFPIA). The views reflect only the authors’ perspective and the JU is not responsible for any use that may be made of the information this manuscript contains.

Elements of the website have been developed under projects from the Biocenter Finland Drug Discovery and Chemical Biology network. CSC-IT is thanked for providing computational resources. Content of the website is provided without guarantee for correctness. Data has been collected and integrated from multiple public sources, for the largest: FDA, HUGO Gene Nomenclature Committee, ChEMBL, IUPHAR/BPS guide to pharmacology, Reactome, UniProt, and Ensembl. Credit is given to Ensembl for collecting species images (provided under public domain licences such as Wikimedia and NHGRI).